Teva Pharmaceutical Industries (2016) A Multinational, Multicenter, Open-Label, Single-Assignment Extension of the MS-LAQ-301 Study, to Evaluate the Long-Term Safety, Tolerability and Effect on Disease Course of Daily Oral Laquinimod 0.6 mg in Subjects with Relapsing Multiple Sclerosis. NCT00988052.

has been cited by the following article:

• TITLE: Treatment of Multiple Sclerosis

  AUTHORS: M. Nadeem, O. Mufti, I. Ahsan, R. Naheed, S. M. Faheem

  KEYWORDS: Immune Sequestration, Multiple Sclerosis, Non-Specific Immune Modulation, Lymphocyte-Targeted Therapy

  JOURNAL NAME: Neuroscience and Medicine, Vol.7 No.2, June 22, 2016

  ABSTRACT: Background: A new method of immune-based therapies has been made and applied on multiple sclerosis patients in last decades. Some of these treatments have a high efficacy and reasonable side effects. In slowing disease progression, present treatments have significant limitations, but often associated with significant adverse effects of immunosuppression, with having a bit low capability to counter the disability. Methods: This is a review meta-analysis of treatment of multiple sclerosis. Results: Thus a valuable aim for multiple sclerosis clinical research is to introduce more effective therapies. Conclusion: It is absolutely necessary to increase the individualized therapy planes development in respect to make better planes to disease-modifying treatments.